This statistic displays the share of non-oncology orphan drugs approved by the European Medicines Agency (EMA) between 2019 and 2022 which were available to patients in selected European countries as of January 5, 2024. According to the data, 85 percent of approved non-oncology orphan medicines were available to patients in Germany, followed by 68 percent in France.
Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country
47 non-oncology orphan drug products were approved by the European Medicines Agency between 2019 and 2022. In most countries availability equates to granting of access to the reimbursement list, except in DK, FI, LU. NO, SE some hospital products are not covered by the general reimbursement scheme. * Country did not complete a full dataset and therefore availability may be unrepresentative. ** In Spain, the WAIT analysis does not identify those medicinal products being accessible earlier in conformity with Spain's Royal Decree 1015/2009 relating to Medicines in Special Situations.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA, & EFPIA. (June 25, 2024). Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/
IQVIA, und EFPIA. "Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country." Chart. June 25, 2024. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/
IQVIA, EFPIA. (2024). Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/
IQVIA, and EFPIA. "Percentage of Non-oncology Orphan Drugs Approved by The Ema Available to Patients in Europe as of 2024, by Country." Statista, Statista Inc., 25 Jun 2024, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/
IQVIA & EFPIA, Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/ (last visited November 10, 2024)
Percentage of non-oncology orphan drugs approved by the EMA available to patients in Europe as of 2024, by country [Graph], IQVIA, & EFPIA, June 25, 2024. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1248699/rate-of-non-oncology-orphan-medicine-availability-europe-by-country/
